Gerald Laurence Murray

Gerald Laurence Murray

Auto-generated profile, based on publicly available information

Gerald Laurence Murray

The University of Melbourne, Melbourne

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2015 in Seminars in Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
PDF file
GMGerald L. Murray
Gerald L. Murray
APAnton Peleg
Anton Peleg
YDYohei Doi
Yohei Doi
The first decade of the 20th century witnessed a surge in the incidence of infections due to several highly antimicrobial-resistant bacteria in hospitals worldwide. Acinetobacter baumannii is one such organism that turned from an occasional respiratory pathogen into a major nosocomial pathogen. An increasing number of A. baumannii genome sequences have broadened our understanding of the genetic makeup of these bacteria and highlighted the extent of horizontal transfer of DNA. Animal models of disease combined with bacterial mutagenesis have provided some valuable insights into mechanisms of A. baumannii pathogenesis. Bacterial factors known to be important for disease include outer membrane porins, surface structures including capsule and lipopolysaccharide, enzymes such as phospholipase D, iron acquisition systems, and regulatory proteins. A. baumannii has a propensity to accumulate resistance to various groups of antimicrobial agents. In particular, carbapenem resistance has become commonplace, accounting for the majority of A. baumannii strains in many hospitals today. Carbapenem-resistant strains are often resistant to all other routinely tested agents. Treatment of carbapenem-resistant A. baumannii infection therefore involves the use of combinations of last resort agents such as colistin and tigecycline, but the efficacy and safety of these approaches are yet to be defined. Antimicrobial-resistant A. baumannii has high potential to spread among ill patients in intensive care units. Early recognition and timely implementation of appropriate infection control measures is crucial in preventing outbreaks.

19 February 2003 in Molecular Microbiology
Verified
Journal Article
Closed access
PDF file
GMGerald L. Murray
Gerald L. Murray
SAStephen R. Attridge
Stephen R. Attridge
RMRenato Morona
Renato Morona

5 June 2018 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
TRTim R H Read
Tim R H Read
CFChristopher K Fairley
Christopher K Fairley
GMGerald L Murray
Gerald L Murray
JJJorgen S Jensen
Jorgen S Jensen
JDJennifer Danielewski
Jennifer Danielewski
CBCatriona S Bradshaw
Catriona S Bradshaw
Rising macrolide and quinolone resistance in Mycoplasma genitalium necessitate new treatment approaches. We evaluated outcomes of sequential antimicrobial therapy for M. genitalium guided by a macrolide-resistance assay. In mid-2016, Melbourne Sexual Health Centre switched from azithromycin to doxycycline (100 mg twice daily for 7 days) for nongonococcal urethritis, cervicitis, and proctitis. Cases were tested for M. genitalium and macrolide-resistance mutations (MRMs) by polymerase chain reaction. Directly after doxycycline, MRM-negative infections received 2.5 g azithromycin (1 g, then 500 mg daily for 3 days), and MRM-positive infections received sitafloxacin (100 mg twice daily for 7 days). Assessment of test of cure and reinfection risk occurred 14–90 days after the second antibiotic. Of 244 evaluable M. genitalium infections (52 women, 68 heterosexual men, 124 men who have sex with men) diagnosed from 20 June 2016 to 15 May 2017, MRMs were detected in 167 (68.4% [95% confidence interval {CI}, 62.2%–74.2%]). Treatment with doxycycline decreased bacterial load by a mean 2.60 log10 (n = 56; P < .0001). Microbiologic cure occurred in 73 of 77 MRM-negative infections (94.8% [95% CI, 87.2%–98.6%]) and in 154 of 167 MRM-positive infections (92.2% [95% CI, 87.1%–95.8%]). Selection of macrolide resistance occurred in only 2 of 76 (2.6% [95% CI, .3%–9.2%]) macrolide-susceptible infections. In the context of high levels of antimicrobial resistance, switching from azithromycin to doxycycline for presumptive treatment of M. genitalium, followed by resistance-guided therapy, cured ≥92% of infections, with infrequent selection of macrolide resistance.

23 March 2015 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
CDCarina Dexter
Carina Dexter
GMGerald L Murray
Gerald L Murray
Ian PaulsenIan Paulsen
Ian Paulsen
APAnton Peleg
Anton Peleg
Community-acquired Acinetobacter baumannii (CA-Ab) is a rare but serious cause of community-acquired pneumonia in tropical regions of the world. CA-Ab infections predominantly affect individuals with risk factors, which include excess alcohol consumption, diabetes mellitus, smoking and chronic lung disease. CA-Ab pneumonia presents as a surprisingly fulminant course and is characterized by a rapid onset of fever, severe respiratory symptoms and multi-organ dysfunction, with a mortality rate reported as high as 64%. It is unclear whether the distinct clinical syndrome caused by CA-Ab is because of host predisposing factors or unique bacterial characteristics, or a combination of both. Deepening our understanding of the drivers of overwhelming CA-Ab infection will provide important insights into preventative and therapeutic strategies.

1 April 2006 in Journal of Bacteriology
Verified
Journal Article
Open access
PDF file
GMGerald L. Murray
Gerald L. Murray
SAStephen R. Attridge
Stephen R. Attridge
RMRenato Morona
Renato Morona
A panel of isogenicSalmonella entericaserovar Typhimurium strains that vary only in the length of the O antigen was constructed through complementation of awzzdouble mutant (displaying unregulated O-antigen length) with one of two homologous (wzzSTandwzzfepE) or three heterologous (wzzO139ofVibrio choleraeandwzzSFandwzzpHS-2ofShigella flexneri)wzzgenes. Each gene was functional in theS. entericaserovar Typhimurium host and specified production of O-antigen polymers with lengths typical of those synthesized by the donor bacteria (ranging from 2 to >100 O-antigen repeat units). By use of this panel of strains, it was found that O-antigen length influences invasion/uptake by macrophage cells; this is the first time this has been shown withSalmonella. O-antigen length was confirmed to be related to complement resistance, with a minimum protective length of >4 and <15 repeat units. O antigen of 16 to 35 repeat units was found to activate complement more efficiently than other lengths, but this was unrelated to complement resistance. No evidence was found to suggest that modifying the length of the O-antigen polymer affected expression of the O1, O4, or O5 antigenic factors.

1 May 2017 in Emerging Infectious Diseases
Verified
Journal Article
Open access
GMGerald L. Murray
Gerald L. Murray
CBCatriona S. Bradshaw
Catriona S. Bradshaw
MBMelanie Bissessor
Melanie Bissessor
JDJennifer Danielewski
Jennifer Danielewski
SGSuzanne M. Garland
Suzanne M. Garland
STSepehr N. Tabrizi
Sepehr N. Tabrizi
Escalating resistance to azithromycin and moxifloxacin is being reported for Mycoplasma genitalium in the Asia-Pacific region. Analyzing 140 infections, we found pretreatment fluoroquinolone-resistance mutations in parC (13.6%) and gyrA (5%). ParC S83 changes were associated with moxifloxacin failure. Combined macrolide/fluoroquinolone-resistance mutations were in 8.6% of specimens, for which recommended therapies would be ineffective.